In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: 1. “How I Treat Peripheral T-cell Lymphoma?”:
https://pubmed.ncbi.nlm.nih.gov/24615779/2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas:
https://pubmed.ncbi.nlm.nih.gov/34921960/

3. Ro-CHOP Phase III study (LYSA): Romidepsin-CHOP vs CHOP in peripheral T-cell lymphoma:
https://pubmed.ncbi.nlm.nih.gov/34843406/

4. RCT of autologous vs allogeneic HSCT as part of 1st line therapy in poor risk peripheral T-cell lymphoma:
https://pubmed.ncbi.nlm.nih.gov/33512419/

5. A phase 2 biomarker-driven study of ruxolitinib in T-cell lymphomas:
https://pubmed.ncbi.nlm.nih.gov/34653242/

6. JACKPOT8 study: Selective JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma:
https://ash.confex.com/ash/2020/webprogram/Paper134650.html